about
Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer.Loss of p53 and acquisition of angiogenic microRNA profile are insufficient to facilitate progression of bladder urothelial carcinoma in situ to invasive carcinomaSpecific activation of K-RasG12D allele in the bladder urothelium results in lung alveolar and vascular defects.Prognostic evaluation of febrile neutropenia in apparently stable adult cancer patients.Loss of β1-integrin from urothelium results in overactive bladder and incontinence in mice: a mechanosensory rather than structural phenotype.Association of anthracycline-related cardiac histological lesions with NADPH oxidase functional polymorphismsStress-induced hyperglycemia is a valuable biomarker in febrile neutropenia.Predicting serious complications in patients with cancer and pulmonary embolism using decision tree modelling: the EPIPHANY Index.Antithrombin controls tumor migration, invasion and angiogenesis by inhibition of enteropeptidase.On the necessity of new decision-making methods for cancer-associated, symptomatic, pulmonary embolism.Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study.Effects of conventional neoadjuvant chemotherapy for breast cancer on tumor angiogenesis.Acute rhabdomyolysis as a complication of paclitaxel-gemcitabine chemotherapy for ovarian cancer.Should anticoagulation therapy be withheld in patients with active cancer after 6 months of low-molecular weight heparin?Circulating small-sized endothelial microparticles as predictors of clinical outcome after chemotherapy for breast cancer: an exploratory analysis.Angiogenic role of miR-20a in breast cancer.Role of oncogenic pathways and KRAS/BRAF mutations in the behavior of colon adenocarcinoma in renal transplant patients.Role of Genetic Polymorphisms in NFKB-Mediated Inflammatory Pathways in Response to Primary Chemoradiation Therapy for Rectal CancerPredictive value of peripheral blood lymphocyte count in breast cancer patients treated with primary chemotherapyValidation of the targeted axillary dissection technique in the axillary staging of breast cancer after neoadjuvant therapy: Preliminary resultsClinical and biological impact of miR-18a expression in breast cancer after neoadjuvant chemotherapyAtrial Fibrillation in Active Cancer Patients: Expert Position Paper and RecommendationsSEOM clinical guidelines in early stage breast cancer (2018)SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018)
P50
Q35000651-74781A7D-207A-44B9-A8FE-ED011F96DD2CQ35063395-66B03FFE-BB11-4C04-B944-D31E3113C59DQ35156169-31063618-4469-42BA-B1E6-F18AF2A74356Q35287593-BEB9EFA7-E37E-4D4A-87F9-62FA2D5F8846Q36788751-596D6572-AA18-4660-8244-DF7A92101453Q36804526-BC038198-78B8-435E-9DBB-6A06715A9BA9Q39723258-A0B9BBD8-67FE-4B7E-B1A2-26EF651451C3Q40304799-E623B305-CC94-462D-A735-44A9915CA02CQ40714729-EE20919D-4DCD-4458-8963-2F795CDA65C8Q40743254-EECE574C-1EB1-4DC3-AC30-B4855594C5FDQ41563223-7628981E-2D6B-4EAB-9507-BFB0DCF418DEQ41742917-8DC4F216-71C3-4D6C-895B-DD2CA1D23272Q45989846-985E8907-897C-4FA3-ACCE-77FE36F998F9Q47393863-28E6AA4C-D49D-4224-8D51-382F298EDDE3Q48230021-C0881A9F-29F6-48B8-B263-84AD5C299E98Q53698485-C72AD1B1-4DAF-4E54-9056-5575C2F44033Q54536258-57F6C031-963C-418D-8D6B-9CD2BED8AD0BQ56217263-251B3598-F18C-4D5B-83A3-60985A16B1BDQ56217278-195FF94D-1B71-4220-A7EB-1F273EC3A5A1Q89999101-3ACEBCFF-433F-400C-9EDE-4A096C15B0A6Q92210522-363C492C-0136-496F-A01B-CFA1B02A32F8Q92575235-D9872823-581A-422E-A430-9BEC59F1D773Q93167667-C51369F4-F411-41D3-8041-53F245619EE0Q93337882-0DED5720-DFE8-451A-8048-447E0893EAEA
P50
description
oncologist at University of Murcia
@en
oncoloog
@nl
onkolog Murcia Universitet
@da
name
Francisco Ayala de la Peña
@ast
Francisco Ayala de la Peña
@da
Francisco Ayala de la Peña
@de
Francisco Ayala de la Peña
@en
Francisco Ayala de la Peña
@es
Francisco Ayala de la Peña
@fo
Francisco Ayala de la Peña
@fr
Francisco Ayala de la Peña
@is
Francisco Ayala de la Peña
@kl
Francisco Ayala de la Peña
@nb
type
label
Francisco Ayala de la Peña
@ast
Francisco Ayala de la Peña
@da
Francisco Ayala de la Peña
@de
Francisco Ayala de la Peña
@en
Francisco Ayala de la Peña
@es
Francisco Ayala de la Peña
@fo
Francisco Ayala de la Peña
@fr
Francisco Ayala de la Peña
@is
Francisco Ayala de la Peña
@kl
Francisco Ayala de la Peña
@nb
altLabel
Francisco Ayala de la Pena
@da
Francisco Ayala de la Pena
@de
Francisco Ayala de la Pena
@en
Francisco Ayala
@da
Francisco Ayala
@de
Francisco Ayala
@en
prefLabel
Francisco Ayala de la Peña
@ast
Francisco Ayala de la Peña
@da
Francisco Ayala de la Peña
@de
Francisco Ayala de la Peña
@en
Francisco Ayala de la Peña
@es
Francisco Ayala de la Peña
@fo
Francisco Ayala de la Peña
@fr
Francisco Ayala de la Peña
@is
Francisco Ayala de la Peña
@kl
Francisco Ayala de la Peña
@nb
P1053
C-5280-2011
P106
P2038
Francisco_Ayala_De_La_Pena
P21
P31
P3829
P496
0000-0001-6311-920X